Detection of cancer cells in the cerebrospinal fluid: Current methods and future directions

Fluids and Barriers of the CNS

Volumn 8, Issue 1, 2011, Pages

  Weston, Cody L ^a   Glantz, Michael J ^a   Connor, James R ^a  

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GADOLINIUM; MOLECULAR MARKER; PEPTIDE; QUANTUM DOT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TUMOR MARKER;

BRAIN LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER THERAPY; CAPILLARY ELECTROPHORESIS; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CONTRAST RADIOGRAPHY; DIAGNOSTIC ACCURACY; DIPLOPIA; EARLY INTERVENTION; FLOW CYTOMETRY; FLUORESCENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GLIOMA; GOLD STANDARD; HEAD AND NECK CANCER; HEADACHE; HEMATOLOGIC MALIGNANCY; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LARGE CELL LYMPHOMA; LASER INDUCED FLUORESCENCE; LEPTOMENINGEAL METASTASIS; LEPTOMENINX; LEUKEMIA; LUNG CANCER; LYMPHOMA; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MELANOMA; MENTAL HEALTH; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY TUMOR; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SENSITIVITY AND SPECIFICITY; SENSORY DYSFUNCTION; SOLID TUMOR; UROGENITAL TRACT TUMOR; WEAKNESS;

EID: 80051728610     PISSN: None     EISSN: 20458118     Source Type: Journal    
DOI: 10.1186/2045-8118-8-14     Document Type: Review

References (80)

1. Chamberlain MC. Neoplastic Meningitis. The Oncologist 2008, 13:967-977. 10.1634/theoncologist.2008-0138, 18776058.
2. Mammoser AG, Groves MD. Biology and therapy of neoplastic meningitis. Curr Oncol Rep 2010, 12:41-49. 10.1007/s11912-009-0079-2, 20425607.
3. Clarke J, Perez H, Jacks L, Panageas K, Deangelis L. Leptomeningeal metastasis in the MRI Era. Neurology 2010, 74:1449-1454. 10.1212/WNL.0b013e3181dc1a69, 20439847.
4. Nolan CP, Abrey LE. Leptomeningeal metastases from leukemias and lymphomas. Cancer Treat Res 2005, 125:53-69. full_text, 16211883.
5. Chamberlain MC, Glantz M, Groves MD, Wilson WH. Diagnostic Tools for Neoplastic Meningitis: Detecting Disease, Identifying Patient Risk, and Determining Benefit of Treatment. YSONC 2010, 36:S35-S45.
6. Glantz MJ, Cole BF, Glantz LK, Cobb J, Mills P, Lekos A, Walters BC, Recht LD. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998, 82:733-739. 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z, 9477107.
7. Dux R, Kindler-Röhrborn A, Annas M, Faustmann P, Lennartz K, Zimmermann CW. A standardized protocol for flow cytometric analysis of cells isolated from cerebrospinal fluid. J Neurol Sci 1994, 121:74-78. 10.1016/0022-510X(94)90159-7, 7510788.
8. Gupta R, Naran S, Lallu S, Fauck R. Cytodiagnosis of neoplasms of the central nervous system in cerebrospinal fluid samples with an application of selective immunostains in differentiation. Cytopathology 2004, 15:38-43. 10.1046/j.1365-2303.2003.00112.x, 14748790.
9. Chamberlain M. Radioisotope CSF flow studies in leptomeningeal metastases. J Neurooncol 1998, 38:135-140. 10.1023/A:1005982826121, 9696363.
10. Gajjar A, Fouladi M, Walter AW, Thompson SJ, Reardon DA, Merchant TE, Jenkins JJ, Liu A, Boyett JM, Kun LE, Heideman RL. Comparison of lumbar and shunt cerebrospinal fluid specimens for cytologic detection of leptomeningeal disease in pediatric patients with brain tumors. J Clin Oncol 1999, 17:1825-1828.
11. Rogers LR, Duchesneau PM, Nunez C, Fishleder AJ, Weick JK, Bauer LJ, Boyett JM. Comparison of cisternal and lumbar CSF examination in leptomeningeal metastasis. Neurology 1992, 42:1239-1241.
12. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995, 38:51-57. 10.1002/ana.410380111, 7611725.
13. Enting RH. Leptomeningeal neoplasia: epidemiology, clinical presentation, CSF analysis and diagnostic imaging. Cancer Treat Res 2005, 125:17-30. full_text, 16211881.
14. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999, 246:810-814. 10.1007/s004150050459, 10525979.
15. Coakham H, Brownell B, Harper E, Garson J, Allan P, Lane E, Kemshead J. Use of monoclonal antibody panel to identify malignant cells in cerebrospinal fluid. Lancet 1984, 323:1095-1098.
16. Ho IAW, Hui KM, Lam PYP. Isolation of peptide ligands that interact specifically with human glioma cells. Peptides 2010, 31:644-650. 10.1016/j.peptides.2009.12.020, 20026365.
17. Lee S, Xie J, Chen X. Peptide-based probes for targeted molecular imaging. Biochemistry 2010, 49:1364-1376. 10.1021/bi901135x, 2829605, 20102226.
18. Kuan CT, Wakiya K, Keir ST, Li J, Herndon JE, Pastan I, Bigner DD. Affinity-matured anti-glycoprotein NMB recombinant immunotoxins targeting malignant gliomas and melanomas. Int J Cancer 2010,
19. Allen JE, El-Deiry WS. Circulating Tumor Cells and Colorectal Cancer. Curr Colorectal Cancer Rep 2010, 6:212-220. 10.1007/s11888-010-0069-7, 2946252, 20890370.
20. Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr Opin Oncol 2010, 22:552-558. 10.1097/CCO.0b013e32833de186, 20706122.
21. Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn 2006, 6:231-244. 10.1586/14737159.6.2.231, 16512782.
22. Wu X, Liu H, Liu J, Haley KN, Treadway JA, Larson JP, Ge N, Peale F, Bruchez MP. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol 2003, 21:41-46. 10.1038/nbt764, 12459735.
23. Tavares AJ, Chong L, Petryayeva E, Algar WR, Krull UJ. Quantum dots as contrast agents for in vivo tumor imaging: progress and issues. Anal Bioanal Chem 2010, 1-12.
24. Resch-Genger U, Grabolle M, Cavaliere-Jaricot S, Nitschke R, Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat Methods 2008, 5:763-775. 10.1038/nmeth.1248, 18756197.
25. Chen C, Xia HS, Gong YP, Peng J, Peng CW, Hu MB, Zhu XB, Pang DW, Sun SR, Li Y. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis. Biomaterials 2010, 31:8818-8825. 10.1016/j.biomaterials.2010.07.091, 20723971.
26. Biju V, Mundayoor S, Omkumar RV, Anas A, Ishikawa M. Bioconjugated quantum dots for cancer research: Present status, prospects and remaining issues. Biotechnol Adv 2010, 28:199-213. 10.1016/j.biotechadv.2009.11.007, 19969062.
27. Hu M, He Y, Song S, Yan J, Lu H, Weng L, Wang L, Fan C. DNA-bridged bioconjugation of fluorescent quantum dots for highly sensitive microfluidic protein chips. Chem Commun (Camb) 2010, 46:6126-6128. 10.1039/c0cc01608j, 20664878.
28. Nuckel H, Novotny J, Noppeney R, Savidou I, Duhrsen U. Detection of malignant haematopoietic cells in the cerebrospinal fluid by conventional cytology and flow cytometry. Clin Lab Haem 2006, 28:22-29.
29. Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM, Dunleavy K, Jaffe ES, Abati A, Stetler-Stevenson M, Wilson WH. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005, 105:496-502. 10.1182/blood-2004-05-1982, 15358629.
30. Aune MW, Becker JL, Brugnara C, Canfield W, Dorfman DM, Fiehn W, Fischer G, Fitzpatrick P, Flaming TH, Henriksen H-K, Kunicka JE, Lackner KJ, Minchello E, Mullenix PA, Myers M, Petersen A, Ternstrom W, Wilson SJ. Automated flow cytometric analysis of blood cells in cerebrospinal fluid: analytic performance. Am J Clin Pathol 2004, 121:690-700. 10.1309/EKFW9E3LLFXE15X9, 15151209.
31. Quijano S, López A, Manuel Sancho J, Panizo C, Debén G, Castilla C, Antonio García-Vela J, Salar A, Alonso-Vence N, González-Barca E, Peñalver FJ, Plaza-Villa J, Morado M, García-Marco J, Arias J, Briones J, Ferrer S, Capote J, Nicolás C, Orfao A, . NHL SGftSoCDi Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009, 27:1462-1469. 10.1200/JCO.2008.17.7089, 19224854, NHL SGftSoCDi.
32. Sancho JM, Orfao A, Quijano S, Garcia O, Panizo C, Perez-Ceballos E, Deben G, Salar A, Gonzalez-Barca E, Alonso N, Garcia-Vela JA, Capote J, Penalver FJ, Provencio M, Arias J, Plaza J, Caballero D, Morado M, Feliu E, Ribera JM. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era. Eur J Haematol 2010, 85:321-328. 10.1111/j.1600-0609.2010.01478.x, 20528905.
33. Strik H, Luthe H, Nagel I, Ehrlich B, Bahr M. Automated cerebrospinal fluid cytology: limitations and reasonable applications. Anal Quant Cytol Histol 2005, 27:167-173.
34. Heller T, Nagel I, Ehrlich B, Bahr M, Strik H. Automated cerebrospinal fluid cytology. Anal Quant Cytol Histol 2008, 30:139-144.
35. van Oostenbrugge RJ, Hopman AH, Lenders MH, van Heerde P, Arends JW, Ramaekers FC, Twijnstra A. Detection of malignant cells in cerebrospinal fluid using fluorescence in situ hybridization. J Neuropathol Exp Neurol 1997, 56:743-748.
36. Park IH, Kwon Y, Ro JY, Lee KS, Ro J. Concordant HER2 status between metastatic breast cancer cells in CSF and primary breast cancer tissue. Breast Cancer Res Treat 2010, 123:125-128. 10.1007/s10549-009-0627-3, 19916047.
37. Galoin S, Daste G, Apoil PA, Chollet F, Roda D, Blancher A, Delsol G, Chittal S, al Saati T. Polymerase chain reaction on cerebrospinal fluid cells in the detection of leptomeningeal involvement by B-cell lymphoma and leukaemia: a novel strategy and its implications. Br J Haematol 1997, 99:122-130. 10.1046/j.1365-2141.1997.3423153.x, 9359512.
38. Rhodes CH, Glantz MJ, Glantz L, Lekos A, Sorenson GD, Honsinger C, Levy NB. A comparison of polymerase chain reaction examination of cerebrospinal fluid and conventional cytology in the diagnosis of lymphomatous meningitis. Cancer 1996, 77:543-548. 10.1002/(SICI)1097-0142(19960201)77:3<543::AID-CNCR17>3.0.CO;2-4, 8630963.
39. Hoon DS, Kuo CT, Wascher RA, Fournier P, Wang HJ, O'Day SJ. Molecular detection of metastatic melanoma cells in cerebrospinal fluid in melanoma patients. J Invest Dermatol 2001, 117:375-378. 10.1046/j.0022-202x.2001.01417.x, 11511319.
40. Dono M, Ferro P, Benedetti L, Capellini C, Moroni M, Dessanti P, Bacigalupo B, Tartaglione A, Battolla E, Fedeli F, Roncella S. Molecular detection of human mammaglobin in cerebrospinal fluid from breast cancer patient with leptomeningeal carcinomatosis. J Neurooncol 2009, 91:295-298. 10.1007/s11060-008-9711-5, 18841443.
41. Hug A, Storch-Hagenlocher B, Haas J, Vogt-Schaden ME, Goldschmidt H, Wildemann B. Single-cell PCR analysis of the immunoglobulin heavy-chain CDR3 region for the diagnosis of leptomeningeal involvement of B-cell malignancies using standard cerebrospinal fluid cytospins. J Neurol Sci 2004, 219:83-88. 10.1016/j.jns.2003.12.012, 15050442.
42. Schold SC, Wasserstrom WR, Fleisher M, Schwartz MK, Posner JB. Cerebrospinal fluid biochemical markers of central nervous system metastases. Ann Neurol 1980, 8:597-604. 10.1002/ana.410080609, 7212647.
43. Jacobi C, Reiber H, Felgenhauer K. The clinical relevance of locally produced carcinoembryonic antigen in cerebrospinal fluid. J Neurol 1986, 233:358-361. 10.1007/BF00313922, 3806144.
44. Corsini E, Bernardi G, Gaviani P, Silvani A, Grazia U, Ciusani E, Croci D, Salmaggi A. Intrathecal synthesis of tumor markers is a highly sensitive test in the diagnosis of leptomeningeal metastasis from solid cancers. Clin Chem Lab Med 2009, 47:874-879. 10.1515/CCLM.2009.183, 19453289.
45. Ladisch S, Chang F, Li R, Cogen P, Johnson D. Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid. Cancer Lett 1997, 120:71-78. 10.1016/S0304-3835(97)00297-8, 9570388.
46. Schliep G, Felgenhauer K. Serum-CSF protein gradients, the blood-GSF barrier and the local immune response. J Neurol 1978, 218:77-96. 10.1007/BF02402169, 78976.
47. Nouadje G, Rubie H, Chatelut E, Canal P, Nertz M, Puig P, Couderc F. Child cerebrospinal fluid analysis by capillary electrophoresis and laser-induced fluorescence detection. J Chromatogr A 1995, 717:293-298. 10.1016/0021-9673(95)00747-3, 8520681.
48. Bayle C, Siri N, Poinsot V, Treilhou M, Causse E, Couderc F. Analysis of tryptophan and tyrosine in cerebrospinal fluid by capillary electrophoresis and "ball lens" UV-pulsed laser-induced fluorescence detection. J Chromatogr A 2003, 1013:123-130. 10.1016/S0021-9673(03)00939-7, 14604114.
49. Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics?. Clin Chem 2003, 49:1272-1275. 10.1373/49.8.1272, 12881441.
50. Dekker LJ, Boogerd W, Stockhammer G, Dalebout JC, Siccama I, Zheng P, Bonfrer JM, Verschuuren JJ, Jenster G, Verbeek MM, Luider TM, Smitt PAS. MALDI-TOF mass spectrometry analysis of cerebrospinal fluid tryptic peptide profiles to diagnose leptomeningeal metastases in patients with breast cancer. Mol Cell Proteomics 2005, 4:1341-1349. 10.1074/mcp.M500081-MCP200, 15970584.
51. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577. 10.1016/S0140-6736(02)07746-2, 11867112.
52. Petricoin EF, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002, 94:1576-1578.
53. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002, 62:3609-3614.
54. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 2002, 48:1835-1843.
55. Khwaja FW, Nolen JD, Mendrinos SE, Lewis MM, Olson JJ, Pohl J, Van Meir EG, Ritchie JC, Brat DJ. Proteomic analysis of cerebrospinal fluid discriminates malignant and nonmalignant disease of the central nervous system and identifies specific protein markers. Proteomics 2006, 6:6277-6287. 10.1002/pmic.200600135, 17078017.
56. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, Groves MD, Kesari S, Pohl J, Van Meir EG. Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 2007, 6:559-570. 10.1021/pr060240z, 2566942, 17269713.
57. Diamandis EP, van der Merwe DE. Plasma protein profiling by mass spectrometry for cancer diagnosis: opportunities and limitations. Clin Cancer Res 2005, 11:963-965.
58. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem 2007, 53:852-858. 10.1373/clinchem.2006.082644, 17395711.
59. Ogata Y, Charlesworth MC, Higgins L, Keegan BM, Vernino S, Muddiman DC. Differential protein expression in male and female human lumbar cerebrospinal fluid using iTRAQ reagents after abundant protein depletion. Proteomics 2007, 7:3726-3734. 10.1002/pmic.200700455, 17853512.
60. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007, 4:51-65. 10.1586/14789450.4.1.51, 17288515.
61. Baggerly KA, Morris JS, Coombes KR. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 2004, 20:777-785. 10.1093/bioinformatics/btg484, 14751995.
62. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006, 52:1223-1237. 10.1373/clinchem.2006.069252, 16644871.
63. Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 1998, 82:923-930. 10.1002/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2, 9486583.
64. Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D, George D, Strother D. Establishment of atypical-teratoid/rhabdoid tumor (AT/RT) cell cultures from disseminated CSF cells: a model to elucidate biology and potential targeted therapeutics. J Neurooncol 2008, 90:171-180. 10.1007/s11060-008-9653-y, 18651103.
65. Sorrentino G, Monsurro MR, Pettinato G, Vanni R, Zuddas A, Di Porzio U, Bonavita V. Establishment and characterization of a human neuroectodermal cell line (TB) from a cerebrospinal fluid specimen. Brain Res 1999, 827:205-209. 10.1016/S0006-8993(99)01197-X, 10320710.
66. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007, 67:4010-4015. 10.1158/0008-5472.CAN-06-4180, 17483311.
67. Peng X-H, Qian X, Mao H, Wang AY, Chen ZG, Nie S, Shin DM. Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy. Int J Nanomedicine 2008, 3:311-321. 2626938, 18990940.
68. Funovics MA, Kapeller B, Hoeller C, Su HS, Kunstfeld R, Puig S, Macfelda K. MR imaging of the her2/neu and 9.2.27 tumor antigens using immunospecific contrast agents. Magn Reson Imaging 2004, 22:843-850. 10.1016/j.mri.2004.01.050, 15234453.
69. Cho H, Dong Z, Pauletti G, Zhang J, Xu H, Gu H, Wang L, Ewing R, Huth C, Wang F, Shi D. Fluorescent, Superparamagnetic Nanospheres for Drug Storage, Targeting, and Imaging: A multifunctional nanocarrier system for cancer diagnosis and treatment. ACS Nano 2010, 4:5398-5404. 10.1021/nn101000e, 20707381.
70. Erogbogbo F, Yong K, Hu R, Law W, Ding H, Chang C, Prasad P, Swihart M. Biocompatible Magnetofluorescent Probes: Luminescent Silicon Quantum Dots Coupled with Superparamagnetic Iron(III) Oxide. ACS Nano 2010, 28:5131-5138.
71. Melisko ME, Glantz M, Rugo HS. New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 2009, 6:25-33. 10.1038/ncponc1243, 18936791.
72. Mori T, Sugita K, Kimura K, Fuke T, Miura T, Kiyokawa N, Fujimoto J. Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement. J Pediatr Hematol Oncol 2003, 25:975-977. 10.1097/00043426-200312000-00014, 14663283.
73. Kolomainen DF, Larkin JM, Badran M, A'Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol 2002, 20:982-986. 10.1200/JCO.20.4.982, 11844820.
74. Mitchell RM, Freeman WM, Randazzo WT, Stephens HE, Beard JL, Simmons Z, Connor JR. A CSF biomarker panel for identification of patients with amyotrophic lateral sclerosis. Neurology 2009, 72:14-19. 10.1212/01.wnl.0000333251.36681.a5, 18987350.
75. Jansen JF, Backes WH, Nicolay K, Kooi ME. 1 H MR spectroscopy of the brain: absolute quantification of metabolites. Radiology 2006, 240:318-332. 10.1148/radiol.2402050314, 16864664.
76. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999, 5:985-990.
77. Yoshino I, Goedegebuure PS, Peoples GE, Parikh AS, DiMaio JM, Lyerly HK, Gazdar AF, Eberlein TJ. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. Cancer Res 1994, 54:3387-3390.
78. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005, 41:107-127. 10.1358/dot.2005.41.2.882662, 15821783.
79. Cheson BD. Monoclonal antibody therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010, 23:133-143. 10.1016/j.beha.2010.01.006, 20620977.
80. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008, 359:613-626. 10.1056/NEJMra0708875, 18687642.